Pharmaceuticals company Neuland Laboratories announced Q4FY24 & FY24 results: FY24 income at Rs 1,571.1 crore, up 30.8% YoY EBITDA at Rs 474.5 crore, up 68.8% YoY Commenting on the performance Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said, “We surpassed revenues of Rs 1,500 crore in FY24 with EBITDA at over 30%. This has been driven by high growth in the CMS business and steady growth of the Specialty GDS business, both of which were in line with our plans and expectations. Another key element is the work on optimizing costs & processes which will also make us truly sustainable.” In addition, Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Laboratories added “Our CMS business saw robust growth in FY24 as some projects are near launch while key commercial products continue to scale. Our growing reputation and the macro-environment are ensuring that exciting opportunities come our way even as we work towards building a further differentiated customer experience. We will continue to invest for the future by adding capacity and capabilities.” Result PDF
Conference Call with Neuland Laboratories Ltd. Management and Analysts on Q3FY24 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Neuland Laboratories announced Q3FY24 & 9MFY24 results: Q3FY24 vs Q4FY23: Total Income: Rs 394.9 crore, showing a growth of 46.2% compared to Q3FY23. EBITDA: Rs 122.7 crore, increased significantly by 123.5% from Q3FY23. EBITDA Margin: 31.1%, improved by 1080 basis points (bps) from Q3FY23. PAT: Rs 80.7 crore, showing a substantial growth of 165.1% compared to Q3FY23. PAT Margin: 20.4%, increased by 910 bps from Q3FY23. EPS (Basic): Rs 62.9, reflecting a growth of 165.1% compared to Q3FY23. 9MFY24 vs 9MFY23: Total Income: Rs 1,180.8 crore, increased significantly by 50.3% compared to 9MFY23. EBITDA: Rs 362.3 crore, showing a substantial growth of 136.4% compared to 9MFY23. EBITDA Margin: 30.7%, improved by 1120 bps from 9MFY23. PAT: Rs 232.0 crore, showing a substantial growth of 195.1% compared to 9MFY23. PAT Margin: 19.6%, increased by 960 bps from 9MFY23. EPS (Basic): Rs 180.8, reflecting a growth of 195.1% compared to 9MFY23. Commenting on the performance Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said, “We are pleased to report another quarter of strong YoY topline growth of 46% to Rs 395 crore. The EBITDA margin of 31.1% is a factor of the business mix as well as improved operational leverage. Even as we see this as a validation of Neuland’s business model, we are focused on continuously improving operations across the company. We are investing both on infrastructure and our people so that we can deliver on our long-term plans.” In addition, Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Laboratories added “Our CMS business saw healthy growth led by commercial as well as projects close to commercialization. The increasing interest from customers with exciting pipelines establishes Neuland’s reputation as a well regarded CDMO. As the quality and size of our business grows, we are gaining a better visibility of our future and planning accordingly.” Result PDF
Conference Call with Neuland Laboratories Ltd. Management and Analysts on Q1FY24 Performance and Outlook. Listen to the full earnings transcript.